<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - LAMOTRIGINE</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>LAMOTRIGINE</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#importantSafetyInformation" data-toggle="tab">Important safety information</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#treatmentCessation" data-toggle="tab">Treatment cessation</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Monotherapy of focal seizures</span>,
                <span class="indication">Monotherapy of primary and secondary generalised tonic-clonic seizures</span>,
                <span class="indication">Monotherapy of seizures associated with Lennox-Gastaut syndrome</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7&#8211;14 days; maintenance 100&#8211;200 mg daily in 1&#8211;2 divided doses; increased if necessary up to 500 mg daily, dose titration should be repeated if restarting after interval of more than 5 days.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7&#8211;14 days; maintenance 100&#8211;200 mg daily in 1&#8211;2 divided doses; increased if necessary up to 500 mg daily, dose titration should be repeated if restarting after interval of more than 5 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunctive therapy of focal seizures with valproate</span>,
                <span class="indication">Adjunctive therapy of primary and secondary generalised tonic-clonic seizures with valproate</span>,
                <span class="indication">Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome with valproate</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 25 mg once daily on alternate days for 14 days, then 25 mg once daily for further 14 days, then increased in steps of up to 50 mg every 7&#8211;14 days; maintenance 100&#8211;200 mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.</li>
              <li class="dose child"><strong>For children 2&#8211;11 years (body-weight up to 13 kg)</strong><br/>
                Initially 2 mg once daily on alternate days for first 14 days, then 300 micrograms/kg once daily for further 14 days, then increased in steps of up to 300 micrograms/kg every 7&#8211;14 days; maintenance 1&#8211;5 mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200 mg per day.</li>
              <li class="dose child"><strong>For children 2&#8211;11 years (body-weight 13 kg and above)</strong><br/>
                Initially 150 micrograms/kg once daily for 14 days, then 300 micrograms/kg once daily for further 14 days, then increased in steps of up to 300 micrograms/kg every 7&#8211;14 days; maintenance 1&#8211;5 mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200 mg per day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 25 mg once daily on alternate days for 14 days, then 25 mg once daily for further 14 days, then increased in steps of up to 50 mg every 7&#8211;14 days; maintenance 100&#8211;200 mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunctive therapy of focal seizures (with enzyme inducing drugs) without valproate</span>,
                <span class="indication">Adjunctive therapy of primary and secondary generalised tonic-clonic seizures (with enzyme inducing drugs) without valproate</span>,
                <span class="indication">Adjunctive therapy of seizures associated with Lennox-Gastaut syndromes (with enzyme inducing drugs) without valproate</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 50 mg once daily for 14 days, then 50 mg twice daily for further 14 days, then increased in steps of up to 100 mg every 7&#8211;14 days; maintenance 200&#8211;400 mg daily in 2 divided doses, increased if necessary up to 700 mg daily, dose titration should be repeated if restarting after interval of more than 5 days.</li>
              <li class="dose child"><strong>For children 2&#8211;11 years</strong><br/>
                Initially 300 micrograms/kg twice daily for 14 days, then 600 micrograms/kg twice daily for further 14 days, then increased in steps of up to 1.2 mg/kg every 7&#8211;14 days; maintenance 5&#8211;15 mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 400 mg per day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 50 mg once daily for 14 days, then 50 mg twice daily for further 14 days, then increased in steps of up to 100 mg every 7&#8211;14 days; maintenance 200&#8211;400 mg daily in 2 divided doses, increased if necessary up to 700 mg daily, dose titration should be repeated if restarting after interval of more than 5 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunctive therapy of focal seizures (without enzyme inducing drugs) without valproate</span>,
                <span class="indication">Adjunctive therapy of primary and secondary generalised tonic-clonic seizures (without enzyme inducing drugs) without valproate</span>,
                <span class="indication">Adjunctive therapy of seizures associated with Lennox-Gastaut syndromes (without enzyme inducing drugs) without valproate</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7&#8211;14 days; maintenance 100&#8211;200 mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.</li>
              <li class="dose child"><strong>For children 2&#8211;11 years</strong><br/>
                Initially 300 micrograms/kg daily in 1&#8211;2 divided doses for 14 days, then 600 micrograms/kg daily in 1&#8211;2 divided doses for further 14 days, then increased in steps of up to 600 micrograms/kg every 7&#8211;14 days; maintenance 1&#8211;10 mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200 mg per day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7&#8211;14 days; maintenance 100&#8211;200 mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Monotherapy or adjunctive therapy of bipolar disorder (without enzyme inducing drugs) without valproate</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 25 mg once daily for 14 days, then 50 mg daily in 1&#8211;2 divided doses for further 14 days, then 100 mg daily in 1&#8211;2 divided doses for further 7 days; maintenance 200 mg daily in 1&#8211;2 divided doses, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens&#8212;consult product literature, dose titration should be repeated if restarting after interval of more than 5 days; maximum 400 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunctive therapy of bipolar disorder with valproate</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 25 mg once daily on alternate days for 14 days, then 25 mg once daily for further 14 days, then 50 mg daily in 1&#8211;2 divided doses for further 7 days; maintenance 100 mg daily in 1&#8211;2 divided doses, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens&#8212;consult product literature, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200 mg per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Adjunctive therapy of bipolar disorder (with enzyme inducing drugs) without valproate</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 50 mg once daily for 14 days, then 50 mg twice daily for further 14 days, then increased to 100 mg twice daily for further 7 days, then increased to 150 mg twice daily for further 7 days; maintenance 200 mg twice daily, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens&#8212;consult product literature, dose titration should be repeated if restarting after interval of more than 5 days.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>




      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="doseAdjustments">
              <p>Halve dose in moderate impairment.</p><p>Quarter dose in severe impairment.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <p>Consider reducing maintenance dose in significant impairment.</p>
            </section>
        
            <section class="generalInformation">
              <p>Caution in renal failure; metabolite may accumulate.</p>
            </section>
      </section>


      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

          <h3>General side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> Blurred vision, aggression, agitation, arthralgia, ataxia, back pain, diarrhoea, diplopia, dizziness, drowsiness, dry mouth, headache, insomnia, nausea, nystagmus, rash, tremor, vomiting,
              </p>
              <p>
                <strong>rare:</strong> Conjunctivitis,
              </p>
              <p>
                <strong>veryRare:</strong> Anaemia, blood disorders, confusion, exacerbation of Parkinson&#8217;s disease in adults, hallucination, hepatic failure, hypersensitivity syndrome, increase in seizure frequency, leucopenia, lupus erythematosus-like reactions, movement disorders, pancytopenia, thrombocytopenia, unsteadiness,
              </p>
              <p>
                <strong>notKnown:</strong> Aseptic meningitis, suicidal ideation,
              </p>
        
        
            <section class="advice">
                <h3>Skin reactions</h3>
              <p>Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have developed (especially in children); most rashes occur in the first 8 weeks. Rash is sometimes associated with hypersensitivity syndrome and is more common in patients with history of allergy or rash from other antiepileptic drugs. Consider withdrawal if rash or signs of hypersensitivity syndrome develop. Factors associated with increased risk of serious skin reactions include concomitant use of valproate, initial lamotrigine dosing higher than recommended, and more rapid dose escalation than recommended.</p>
            </section>
        
      </section>


      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
                <h3>Skin reactions</h3>
              <p>Warn patients and carers to see their doctor immediately if rash or signs or symptoms of hypersensitivity syndrome develop.</p>
            </section>
            <section class="generalPatientAdvice">
                <h3>Blood disorders</h3>
              <p>Patients and their carers should be alert for symptoms and signs suggestive of bone-marrow failure, such as anaemia, bruising, or infection. Aplastic anaemia, bone-marrow depression, and pancytopenia have been associated rarely with lamotrigine.</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Lamotrigine for preventing seizures</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/lamotrigine-for-preventing-seizures">www.medicinesforchildren.org.uk/lamotrigine-for-preventing-seizures</xref>
            </p>
            </section>
      </section>


      <section class="tab-pane" id="importantSafetyInformation">
        <h2>Important safety information</h2>

            <section class="importantSafetyInformation">
                <h3>Safe Practice</h3>
              <p>Do not confuse the different combinations or indications.</p>
            </section>
      </section>

      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
            Myoclonic seizures (may be exacerbated)
          </li>
          <li>
              <strong>:</strong>
            Parkinson&#8217;s disease (may be exacerbated) in adults
          </li>
        </ul>
      </section>




      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <p>Patients being treated for epilepsy may need to be maintained on a specific manufacturer&#8217;s branded or generic lamotrigine product.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
                <h3>Switching between formulations</h3>
              <p>Care should be taken when switching between oral formulations in the treatment of epilepsy. The need for continued supply of a particular manufacturer's product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.</p>
            </section>
      </section>

      <section class="tab-pane" id="treatmentCessation">
        <h2>Advice regarding ceasing treatment</h2>

            <section class="treatmentCessation">
              <p>Avoid abrupt withdrawal (taper off over 2 weeks or longer) unless serious skin reaction occurs.</p>
            </section>
      </section>







      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

        
            <section class="crossSensitivity">
              <p>Antiepileptic hypersensitivity syndrome associated with lamotrigine. See under <xref format="dita" href="#PHP78230" type="bookmark" namespace="/treatment-summaries/epilepsy">Epilepsy</xref> for more information.</p>
            </section>
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of LAMOTRIGINE</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral solution,
            oral suspension,

            <div id="PHP76356"><a href="../medicinalForm/PHP76356.html" data-target="#PHP76356" data-action="load">Tablet</a></div>
            <div id="PHP76363"><a href="../medicinalForm/PHP76363.html" data-target="#PHP76363" data-action="load">Dispersible tablet</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
